ZM-447439 inhibits aurora kinases A and B (AurA, AurB), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer activity, inducing hyperploidy and apoptosis in osteosarcoma cells and inhibiting growth in mesothelioma cells. ZM-447439 also induces apoptosis and inhibits expression of AurB and H3-P protein in cervical cancer cells, suppressing growth and survival.
| Cas No. | 331771-20-1 |
|---|---|
| Purity | ≥99% |
| Formula | C29H31N5O4 • 3H2O |
| Formula Wt. | 567.63 |
| IUPAC Name | N-[4-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl]benzamide |
| Appearance | White to Off-white Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | Z4900 Info Sheet PDF |
|---|
Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer. 2013 Nov 12;109(10):2607-18. PMID: 24129234.
Baldini E, Tuccilli C, Prinzi N, et al. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15. PMID: 24152827.
Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010 Dec;70(3):271-9. PMID: 20371132.
